XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Noncontrolling Interest
Beginning Balance at Dec. 31, 2020 $ 743,266 $ 14 $ 1,253,971 $ 893 $ (511,612)  
Beginning Balance, Shares at Dec. 31, 2020   137,646,896        
Issuance of common stock upon exercise of common stock warrant, Shares   54,162        
Issuance of common stock for cash upon exercise of stock options 20,502   20,502      
Issuance of common stock for cash upon exercise of stock options, Shares   2,950,197        
Vesting of restricted stock units   12,500        
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation 19,733   19,733      
Capital contributions for Digital Biotechnologies, Inc. 429   300     $ 129
Other comprehensive loss (677)     (677)    
Net loss (89,943)       (89,943)  
Ending Balance at Jun. 30, 2021 693,310 $ 14 1,294,506 216 (601,555) 129
Ending Balance, Shares at Jun. 30, 2021   140,663,755        
Beginning Balance at Mar. 31, 2021 725,717 $ 14 1,277,197 631 (552,254) 129
Beginning Balance, Shares at Mar. 31, 2021   139,884,698        
Issuance of common stock for cash upon exercise of stock options 6,060   6,060      
Issuance of common stock for cash upon exercise of stock options, Shares   766,557        
Vesting of restricted stock units   12,500        
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation 11,249   11,249      
Other comprehensive loss (415)     (415)    
Net loss (49,301)       (49,301)  
Ending Balance at Jun. 30, 2021 693,310 $ 14 1,294,506 216 (601,555) 129
Ending Balance, Shares at Jun. 30, 2021   140,663,755        
Beginning Balance at Dec. 31, 2021 604,102 $ 14 1,324,006 (1,137) (718,891) 110
Beginning Balance, Shares at Dec. 31, 2021   141,393,865        
Issuance of common stock for cash upon exercise of stock options $ 6,716   6,716      
Issuance of common stock for cash upon exercise of stock options, Shares 1,230,089 1,230,089        
Vesting of restricted stock units   160,914        
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation $ 27,041   27,041      
Other comprehensive loss (4,663)     (4,663)    
Net loss (114,880)       (114,782) (98)
Ending Balance at Jun. 30, 2022 518,316 $ 14 1,357,763 (5,800) (833,673) 12
Ending Balance, Shares at Jun. 30, 2022   142,784,868        
Beginning Balance at Mar. 31, 2022 553,255 $ 14 1,339,601 (4,783) (781,627) 50
Beginning Balance, Shares at Mar. 31, 2022   142,183,258        
Issuance of common stock for cash upon exercise of stock options 3,982   3,982      
Issuance of common stock for cash upon exercise of stock options, Shares   581,881        
Vesting of restricted stock units   19,729        
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation 14,180   14,180      
Other comprehensive loss (1,017)     (1,017)    
Net loss (52,084)       (52,046) (38)
Ending Balance at Jun. 30, 2022 $ 518,316 $ 14 $ 1,357,763 $ (5,800) $ (833,673) $ 12
Ending Balance, Shares at Jun. 30, 2022   142,784,868